In the last Parallax episode of the year,Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
This year we had a number of studies that helped clarify our understanding of the world of antiplatelets: First, Ankur and Sukh discuss the take-home messages from HOST-EXAM, a Korean study presented at ACC 2021. They discuss their clinical experiences within the UK and US setting. Next, Sukh talks about the STOPDAPT-2 ACS study, presented at ESC 2021. Sukh interprets the findings in the light of TWILIGHTand summarises his thoughts on the therapy.
2021 was not a great year for physiology: Sukh shares his take on FLOWER-MI, presented at ACC 2021. He offers a deep dive into the data and highlights both the importance of the findings and the limitations of the study.
Next, they discuss RIPCORD 2 from ESC 2021 and finally, Sukh highlights the findings from the FAME 3 trial.
What is the importance of genotype testing in the world of antiplatelets? What are the considerations for clinicians? Should we stop using FFR? How can we incorporate novel findings to patient care? What are the practical considerations that we should take into account when looking at the physiology trials of 2021?
Stay tuned for Part 2 - heart failure and surgical trials coming in 2022.
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com
In this edition of Parallax Dr Kalra asked Dr Rosenbaum about the influences that shaped her choices as a writer and as a healthcare professional. Dr Rosenbaum opens up about her childhood and how she connected to her grandfather through writing and medicine. We learn about Lisa’s first day at medical school and her latest writing project.
Jagmeet P Singh, associate chief of the cardiology division at Massachusetts General Hospital and professor of medicine at Harvard Medical School joins Ankur Kalra for a deep conversation about his journey across three continents. Dr Singh talks about the importance of choosing fulfilment over success. We gain more insights on the recent late-breaking trial, MADIT-CHIC focusing on cardiac resynchronization therapy. Ankur asks Jag about his experience of being on the other side of the healthcare system and his enrolment in the since halted remdesivir trial.
Prof Michele Senni is Director of Cardiology at Papa Giovanni XXIII Hospital, Bergamo Italy. He contracted COVID-19 himself and in this latest podcast he meets with Ankur Kalra, MD to discuss his personal experience in dealing with patients and COVID-19 in Europe’s outbreak epicentre.
Hear them discuss the burden on healthcare, patient selection, the importance of testing and PPE and how COVID has resulted in a reduction of acute myocardial infarction and heart failure in patients.
In this latest episode, Ankur Kalra, MD meets with Andrew Sauer, MD, co-author of an upcoming paper in US Cardiology Review on COVID-19 and Cardiovascular Disease that provides a concise and current summary of cardiovascular complications from COVID-19.
Hear them discuss the latest issues surrounding the pandemic, the known cardiac implications and the rapidly emerging data.
Hear Bill’s take on how East Asia responded to and successfully managed the pandemic and how they are now seeing a significant reduction in cases outside the epicentre. Hear how the strategy resulted in only 93 patients in Bill’s city of Nanjing, testing positive for coronavirus with a city population of 8 million.
Learn about effective responses, the importance of early control and how as a cardiovascular physician, your life and practice may be impacted by the virus.
Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.